Dr. Nicholas Scanlon, MD

Dr. Scanlon practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Scanlon's NPI, 1477084606, was assigned on March 21, 2017. Dr. Scanlon graduated from Heersink School of Medicine - Birmingham in 2017. Dr. Scanlon holds California license A175073.

Dr. Scanlon's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Scanlon's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Scanlon is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Scanlon practices. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Scanlon's primary specialty in the NPI Registry, under taxonomy code 207RA0201X. Dr. Scanlon is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Scanlon's licenses on file in 2 states: California and Georgia.

Dmand AI lists chronic nasal allergies among the conditions Dr. Scanlon treats.

CMS data shows 676 Medicare services from Dr. Scanlon across 5 procedure codes in 2024, for 148 Medicare patients. Medicare paid $25,174 for them.

CMS counts 148 Medicare patients who saw Dr. Scanlon in 2024. The largest group is 65 to 74, with 65 patients. 70% of them have high cholesterol, and 59% have high blood pressure. 35% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Scanlon's median patient age at 40, with 67% women.

In 2024, Dr. Scanlon wrote 451 Medicare Part D claims for 113 patients. 76% of them were for generic drugs. CMS names the drug for 363 of them, across 8 drugs with 11 or more claims each, at $177,039 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Scanlon for performance year 2024, reported as part of a group. Dr. Scanlon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Scanlon as offering telehealth.

Dmand AI links 6 papers to Dr. Scanlon, published from 2020 to 2023. 2023 was the busiest year, with 2. Dr. Scanlon's most frequent co-authors are Taylor A. Doherty, MD, Nadine Georges Rouphael, MD and Lori Broderick, MD, PhD.

Dmand AI links Dr. Scanlon to 4 clinical trials, 4 of them phase 3 studies. Conditions studied include COVID-19 and Pneumonia, Viral. National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most, 4.

CMS Open Payments shows 48 general payments to Dr. Scanlon from 15 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $1,247.

Dmand AI lists 4 awards for Dr. Scanlon, most recently Chrysalis Project Award in 2019. Dr. Scanlon serves on Advisory Committee on LGBTQ Issues - American Medical Association.

Dr. Scanlon graduated from Heersink School of Medicine - Birmingham in 2017. Dr. Scanlon is a member of AAAAI, ACAAI, ACP and AMA.

Dr. Scanlon is in network with 12 carriers, including United Healthcare, Elevance and Aetna. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.